Pakistan's pharmaceutical regulatory framework faces a critical accessibility gap as approximately 40 approved life-saving medications remain unavailable to patients despite receiving official registration. This paradox highlights significant challenges in the drug distribution system, affecting vulnerable populations who depend on these essential treatments. The situation raises questions about implementation mechanisms, supply chain bottlenecks, and healthcare equity in Pakistan's medical sector.

Summary auto-generated by AI from the original publisher's content. Editorial standards.